Healthcare
April 18, 2018 / 7:21 AM / 10 months ago

BRIEF-NeuroVive Receives FDA Orphan Drug Designation

1 Min Read

April 18 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:

* NEUROVIVE’S KL1333 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TREATMENT OF MITOCHONDRIAL DISEASES

* ODD OPENS UP FOR MARKET EXCLUSIVITY FOR SEVEN YEARS WITHIN US FOR NEUROVIVE’S KL1333, WHEN AUTHORISED FOR MARKETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below